Abivax SA
abivax.comWhat Do They Do?
Develops drug candidates for chronic inflammatory diseases, including treatments for ulcerative colitis and Crohn’s disease.
20-F for FY2025, filed Mar 23, 2026We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to…View ↗
Our initial focus is on inflammatory bowel diseases ("IBD"), chronic conditions involving inflammation of the gastrointestinal tract, of…View ↗
Our lead drug candidate, obefazimod, is currently in Phase 3 clinical development for the treatment of moderately to severely active UC. We…View ↗
Who Do They Compete With?
Competes with AbbVie, Johnson & Johnson, Takeda, Pfizer, Eli Lilly, Merck, Roche, Teva, Sanofi, Morphic Therapeutic, Protagonist Therapeutics, Gilead, Galapagos, Alfasigma, Bristol Myers Squibb, Ventyx Biosciences, and NImmune Biopharma
20-F for FY2025, filed Mar 23, 2026(vii) manufacturing costs; intellectual property and patent rights and their protection; and (viii) sales and marketing capabilities. Our…View ↗
Loading...
